Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olaparib + bevacizumab
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Olaparib + bevacizumab is a combination therapy used as maintenance treatment for adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer whose tumors are homologous recombination deficiency (HRD)-positive, including those with BRCA mutations. Olaparib is a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes PARP1 and PARP2, which impairs DNA repair in cancer cells and induces cell death. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), blocking angiogenesis and reducing tumor blood supply. The combination leverages both direct cytotoxicity from impaired DNA repair and antiangiogenic effects to improve outcomes in HRD-positive cancers[1][2][3][4][5][6][8].
- Brand names
- AvastinLYNPARZA
- Other names
- olaparib + bevacizumab
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)Pol II (RNA polymerase II elongation factors)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on olaparib + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olaparib + bevacizumab.